1-(3-chlorophenyl)-3-(thiophen-2-ylmethyl)thiourea is an organic compound with a chemical formula C12H11ClN2S2. It is a thiourea derivative that contains both a chlorophenyl and a thiophene group.
**Why is it important for research?**
While specific research on this exact compound might be limited, thiourea derivatives in general are a class of compounds with significant research interest due to their diverse biological activities. Here's why 1-(3-chlorophenyl)-3-(thiophen-2-ylmethyl)thiourea could be of interest to researchers:
* **Potential Anti-Cancer Activity:** Thiourea derivatives have been explored for their potential to inhibit cancer cell growth. The specific structure of this compound could potentially influence its interaction with specific cancer targets.
* **Antimicrobial Properties:** Some thioureas exhibit antimicrobial activity against bacteria and fungi. The combination of the chlorophenyl and thiophene groups might contribute to the compound's antimicrobial potential.
* **Enzyme Inhibition:** Thioureas can act as inhibitors of various enzymes, including those involved in metabolic pathways. This compound could potentially be explored for its ability to inhibit specific enzyme targets.
* **Ligand for Metal Complexes:** The sulfur atoms in the thiourea group can coordinate with metal ions, making this compound a potential ligand for the formation of metal complexes. Metal complexes have applications in areas like catalysis and medicinal chemistry.
**Important Note:** Without specific research on 1-(3-chlorophenyl)-3-(thiophen-2-ylmethyl)thiourea, it is impossible to definitively say why it is important for research. It's essential to look for specific research publications or data related to this particular compound to understand its exact significance.
**To further explore this compound:**
* **Search scientific databases:** Use databases like PubMed, SciFinder, or Google Scholar to look for published research articles on 1-(3-chlorophenyl)-3-(thiophen-2-ylmethyl)thiourea or similar thiourea derivatives.
* **Contact research labs:** Reach out to research groups specializing in organic chemistry, medicinal chemistry, or related fields to inquire about their knowledge of this compound.
ID Source | ID |
---|---|
PubMed CID | 2059105 |
CHEMBL ID | 1422275 |
CHEBI ID | 113099 |
Synonym |
---|
smr000193493 |
MLS000571408 |
AK-968/40426856 |
n-(3-chlorophenyl)-n'-(2-thienylmethyl)thiourea |
STK077054 |
1-(3-chlorophenyl)-3-(thiophen-2-ylmethyl)thiourea |
CHEBI:113099 |
AKOS001636868 |
HMS2446N19 |
AB00100062-01 |
CHEMBL1422275 |
Q27193563 |
SR-01000465062-1 |
sr-01000465062 |
1-(3-chlorophenyl)-3-[(thiophen-2-yl)methyl]thiourea |
Class | Description |
---|---|
thioureas | Compounds of general formula RR'NC(=S)NR''R'''. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 1.4125 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
Smad3 | Homo sapiens (human) | Potency | 3.5481 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
PINK1 | Homo sapiens (human) | Potency | 12.5893 | 2.8184 | 18.8959 | 44.6684 | AID624263 |
Parkin | Homo sapiens (human) | Potency | 12.5893 | 0.8199 | 14.8306 | 44.6684 | AID624263 |
IDH1 | Homo sapiens (human) | Potency | 35.4813 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 12.5893 | 0.0018 | 15.6638 | 39.8107 | AID894 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 24.0682 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
geminin | Homo sapiens (human) | Potency | 29.0929 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |